With the aim of becoming the leading player in the fragmented dermatology market within 5 years, Valeant Pharmaceuticals has continued its deal making in this area by agreeing to acquire the assets of the Ortho Dermatologics division of Johnson & Johnson’s Janssen Pharmaceuticals for US$345 M. The division reported revenues of approximately US$150 M in 2010 from sales of prescription drugs such as Retin-A-Micro® (tretinoin gel), Ertaczo® (sertaconazole nitrate) and Renova® (tretinoin cream).